Literature DB >> 11384791

The prehospital treatment of status epilepticus (PHTSE) study: design and methodology.

D H Lowenstein1, B K Alldredge, F Allen, J Neuhaus, M Corry, M Gottwald, N O'Neil, S Ulrich, S M Isaacs, A Gelb.   

Abstract

Status epilepticus is a neurological emergency that is typically first encountered and managed in the prehospital environment. Although aggressive pharmacological treatment of status epilepticus is well established in the emergency department and hospital settings, the relative risks and benefits of active therapy for status epilepticus in the prehospital setting are not known. The Prehospital Treatment of Status Epilepticus (PHTSE) study is a prospective, randomized, double-blind, placebo-controlled study designed to address the following aims: (1) to determine whether administration of benzodiazepines by paramedics is an effective and safe means of treating status epilepticus in the prehospital setting and whether this therapy influences longer-term patient outcome, (2) to determine whether lorazepam is superior to diazepam for the treatment of status epilepticus in the prehospital setting, and (3) to determine whether control of status epilepticus prior to arrival to the emergency department influences patient disposition. The initial phase of the PHTSE study began in January 1994 and was completed in February 1999 after the successful enrollment of 205 patients into the three treatment arms. In this paper, we describe the rationale for the conceptualization of the study and details of the study design and methodology, and emphasize some aspects of study implementation that are unique to research involving the emergency medical system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384791     DOI: 10.1016/s0197-2456(01)00120-9

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  8 in total

1.  A community consultation survey to evaluate support for and success of the IMMEDIATE trial.

Authors:  Joni R Beshansky; Patricia R Sheehan; Kenneth J Klima; Nira Hadar; Ellen M Vickery; Harry P Selker
Journal:  Clin Trials       Date:  2014-04       Impact factor: 2.486

2.  Challenges in the design and analysis of non-inferiority trials: a case study.

Authors:  Valerie Durkalski; Robert Silbergleit; Daniel Lowenstein
Journal:  Clin Trials       Date:  2011-09-15       Impact factor: 2.486

3.  Intramuscular versus intravenous therapy for prehospital status epilepticus.

Authors:  Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

4.  Design and phenomenology of the FEBSTAT study.

Authors:  Dale C Hesdorffer; Shlomo Shinnar; Darrell V Lewis; Solomon L Moshé; Douglas R Nordli; John M Pellock; James MacFall; Ruth C Shinnar; David Masur; L Matthew Frank; Leon G Epstein; Claire Litherland; Syndi Seinfeld; Jacqueline A Bello; Stephen Chan; Emilia Bagiella; Shumei Sun
Journal:  Epilepsia       Date:  2012-06-28       Impact factor: 5.864

Review 5.  Anticonvulsant therapy for status epilepticus.

Authors:  Manya Prasad; Pudukode R Krishnan; Reginald Sequeira; Khaldoon Al-Roomi
Journal:  Cochrane Database Syst Rev       Date:  2014-09-10

Review 6.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Authors:  Sima I Patel; Angela K Birnbaum; James C Cloyd; Ilo E Leppik
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

7.  Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis.

Authors:  Moira Cruickshank; Mari Imamura; Corinne Booth; Lorna Aucott; Carl Counsell; Paul Manson; Graham Scotland; Miriam Brazzelli
Journal:  Health Technol Assess       Date:  2022-03       Impact factor: 4.106

8.  Prehospital Treatment of Status Epilepticus with Benzodiazepines Is Effective and Safe.

Authors:  Jaideep Kapur
Journal:  Epilepsy Curr       Date:  2002-07       Impact factor: 7.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.